Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257594 · ClinicalTrials.gov registry record · Phase 1
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
A Phase 1 study of Brain Cancer, sponsored by Andrew B Lassman, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 4
- Study locations
NCT01257594 is a Phase 1 study of Brain Cancer that has completed, run by Andrew B Lassman, MD. The registered enrollment target is 22 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT01257594, a Phase 1 study of Brain Cancer, has completed, sponsored by Andrew B Lassman, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to test the effectiveness of a drug called erlotinib in treating the tumor. This is a multi-center pilot study that explores efficacy and molecular effects of high dose weekly erlotinib for recurrent EGFR vIII mutant malignant gliomas, and correlate molecular profile of pre-treatment tissue with outcome.
Conditions Studied
Interventions
- PROCEDURE Cytoreductive Surgery
- DRUG erlotinib
Study Locations (4)
New York
- Memorial Sloan-Kettering Cancer Center at Commack - Commack
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan-Kettering at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-01-07 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01257594
The ClinicalTrials.gov registry entry for NCT01257594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Andrew B Lassman, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cytoreductive Surgery is the first listed.
NCT01257594 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01257594 about?
NCT01257594 is a clinical study titled "EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas". The purpose of this study is to test the effectiveness of a drug called erlotinib in treating the tumor. This is a multi-center pilot study that explores efficacy and molecular effects of high dose weekly erlotinib for recurrent EGFR vIII mutant malignant gliomas, and correlate molecular profile of ...
What is the current status of trial NCT01257594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-01-07. Estimated completion is 2018-12-31.
What conditions does trial NCT01257594 study?
This clinical trial studies the following conditions: Brain Cancer.
What interventions are being tested in trial NCT01257594?
The interventions under investigation include: Cytoreductive Surgery (PROCEDURE), erlotinib (DRUG).
Who is sponsoring clinical trial NCT01257594?
This trial is sponsored by Andrew B Lassman, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01257594 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.